Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for dupilumab (Dupixent) as add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) associated with type 2 inflammation